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Burden of obstetric ﬁ stula: from measurement to act ion
For every maternal death, an additional 20–30 women 
develop serious pregnancy-related complications. 
Among all maternal morbidities, obstetric ﬁ stula is one 
of the most devastating. It is caused by injury during 
childbirth, resulting in an abnormal opening between 
the vagina and the bladder (vesicovaginal ﬁ stula) or 
rectum (rectovaginal ﬁ stula), leading to continuous 
urinary or fecal incontinence. Obstructed labour is the 
most common cause of vesicovaginal ﬁ stula in low-
income countries.1 Worldwide, an estimated 2–3 million 
women have obstetric ﬁ stula,1 almost exclusively 
in sub-Saharan Africa and south Asia. However, this 
is a rough estimate and few data exist about the 
epidemiology of obstetric ﬁ stula. In The Lancet Global 
Health, Mathieu Maheu-Giroux and colleagues2 estimate 
lifetime and point prevalence of vesicovaginal ﬁ stula 
in 19 sub-Saharan African countries. This paper is the 
ﬁ rst to estimate the prevalence of vaginal ﬁ stula (both 
obstetric and from other causes) based on population-
level data from a large number of countries, using 
nationally representative surveys.  
The two most common sources of data for obstetric 
ﬁ stula are medical records and self-reported surveys. 
Medical records grossly underestimate the prevalence 
and incidence of obstetric ﬁ stula, as a result of the 
population aﬀ ected by ﬁ stula and their limited 
access to medical care. Conversely, self-reported 
data from surveys, such as those used by Maheu-
Giroux and colleagues, have low diagnostic value 
for maternal complications. Furthermore, Maheu-
Giroux and colleagues2 limited their sample to women 
aged 15–49 years who were available for household 
interviews; institutionalised women at rehabilitation 
centres, women at facilities undergoing or awaiting 
surgical treatments, and women older than 49 years 
with ﬁ stula were not accounted for. Finally, there is an 
additional risk of misclassiﬁ cation because postpartum 
incontinence is common. Maheu-Giroux and colleagues2 
used Bayesian statistics in an attempt to correct for 
misclassiﬁ cation bias and improve their estimates. Their 
results are crucial for quantifying the disease burden 
and for the development of country-speciﬁ c policy and 
planning strategies to prevent and treat obstetric ﬁ stula.
Take the example of Ethiopia. The ﬁ gure shows the 
numbers of women treated between 2010 and 2013, 
in Ethiopia, Uganda, and Nigeria. Fistula surgery is 
rarely done at private facilities and outside of the listed 
centres, and thus underestimating ﬁ stula surgery is 
unlikely. From 2010 to 2013, on average, fewer than 
2000 women each year had surgery for obstetric ﬁ stula 
in Ethiopia. Maheu-Giroux and colleagues2 show that 
more than 110 000 women in Ethiopia presently have 
vaginal ﬁ stula. These data imply that if no new cases 
occur, it will take at least 55 years to treat the existing 
patients in Ethiopia at the current rate. Clearly, Ethiopia 
has deﬁ ciencies in national treatment planning—
most women will never receive surgical treatment 
despite living in a country with one of the world’s best 
treatment facilities for obstetric ﬁ stula, including a 
dedicated ﬁ stula treatment and training facility at 
Addis Ababa Fistula Hospital. The situation in other 
countries is unlikely to be better.
All cases of obstetric ﬁ stula can be prevented with 
timely access to emergency obstetric care, especially 
caesarean section. Obstetric ﬁ stula was virtually 
eliminated in Europe and the USA between 1935 and 
1950, because of universal access to safe delivery care. 
That it is still a public health problem in some countries 
shows the enormous gap in maternal health care 
between high-income and low-income nations and 
is a result of the egregious failure of health systems 
in these regions to provide safe maternity care. Poor 
women without timely access to safe intrapartum care 
are most vulnerable to obstetric ﬁ stula and the physical 
and psychological consequences aﬀ ect quality of life.4 
Aﬀ ected women are often abandoned by their husbands 
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Figure: Treatment for obstetric ﬁ stula in three countries (2010–13) 
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and families, and ostracised by their communities. In 
many societies, obstetric ﬁ stula is stigmatised. It is not 
surprising that these women have been considered as 
“the most dispossessed, outcast, powerless group of 
women in the world”.5
Since the initiation of the “Campaign to End Fistula” 
by UNFPA and other organisations in 2003, awareness 
among policy makers has signiﬁ cantly increased. 
However, the lack of reliable data for prevalence 
and incidence has hampered eﬀ orts to formulate an 
appropriate and coordinated response to obstetric 
ﬁ stula. The collection of accurate and reliable maternal 
morbidity data in low-income countries is diﬃ  cult, 
especially for obstetric ﬁ stula.6,7 
Estimation of the burden of obstetric ﬁ stula in 
low-income countries is still a challenge. At a recent 
meeting,8 an urgent call was made to develop 
appropriate methods for measuring national burdens 
of obstetric ﬁ stula so that eﬀ ective maternal health care 
can be developed. Obstetric ﬁ stula disproportionately 
aﬀ ects the poorest women, whose voices are scarcely 
heard. Every life counts and we hope that the need for 
better data to inform decision-making and planning 
at the national level will be recognised in international 
and national safe motherhood agendas and appropriate 
resources will be mobilised to collect reliable data about 
obstetric ﬁ stula.   
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